Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Equity Ratio (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Equity Ratio for 7 consecutive years, with 0.02 as the latest value for Q3 2019.

  • For the quarter ending Q3 2019, Equity Ratio fell 97.41% year-over-year to 0.02, compared with a TTM value of 0.02 through Sep 2019, down 97.41%, and an annual FY2018 reading of 0.02, down 96.77% over the prior year.
  • Equity Ratio was 0.02 for Q3 2019 at Larimar Therapeutics, up from 0.01 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.94 in Q1 2015 and bottomed at 0.01 in Q2 2019.
  • Average Equity Ratio over 5 years is 0.69, with a median of 0.91 recorded in 2016.
  • The sharpest move saw Equity Ratio increased 6.61% in 2015, then tumbled 99.2% in 2019.
  • Year by year, Equity Ratio stood at 0.89 in 2015, then grew by 3.42% to 0.92 in 2016, then dropped by 19.84% to 0.74 in 2017, then plummeted by 96.77% to 0.02 in 2018, then decreased by 14.66% to 0.02 in 2019.
  • Business Quant data shows Equity Ratio for LRMR at 0.02 in Q3 2019, 0.01 in Q2 2019, and 0.01 in Q1 2019.